Invitrogen™ CD137 Ligand (4-1BB Ligand) Monoclonal Antibody (5G11), eBioscience™, Invitrogen™

Description

This 5G11 monoclonal antibody recognizes human CD137 ligand also known as 4-1BB ligand, TNFSF9, or CDw137L. CD137 ligand is a member of the TNF superfamily, and is a type II membrane protein. It is a co-stimulatory molecule that is expressed on antigen presenting cells (DCs, monocytes/macrophages, B cells) and is upregulated upon activation of these cells. Its receptor, CD137 (4-1BB) is found on a variety of cells, including inflamed endothelial cells, where it enhances extravasation of CD137 ligand-expressing monocytes. Activated T cells also express CD137, and engagement with CD137 ligand enhances T cell proliferation, IL-2 secretion, survival, and cytotoxic activity. CD137 ligand is also expressed on a majority of B-cell lymphomas, including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma (but not on Hodgkin lymphoma and T-cell lymphoma). This 5G11 antibody has been tested by immunohistochemical staining of formalin-fixed paraffin embedded human tissue using low pH antigen retreival and can be used at less than or equal to 1 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD137 ligand (CD137L) is a type II membrane protein and part of the TNF superfamily. CD137L is a co-stimulatory molecule that is expressed on antigen presenting cells (DCs, monocytes/macrophages, B cells) and is upregulated upon activation. Its receptor, CD137/4-1BB, is found on a variety of cells, including inflamed endothelial cells, where its expression enhances extravasation of CD137L expressing monocytes. Activated T cells also express CD137, and engagement with CD137L enhances T cell proliferation, IL-2 secretion, survival, and cytotoxic activity. CD137L is also expressed on a majority of B-cell lymphomas, including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma (but it is lacking on Hodgkin lymphoma and T-cell lymphoma). CD137L is also expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interactions.